Eric Schmidt reportedly holds 1% of Anthropic: the IPO will reward a former Google CEO's early bet

By Bloomberg · October 19, 2026.

Eric Schmidt, former CEO of Google, owns roughly 1% of Anthropic, Bloomberg reports, citing people familiar with the matter who asked not to be identified. He reportedly bought in with an investment of tens of millions of dollars in the company's Series A round (a startup's first major outside funding).

According to those sources, that stake would put him in line for one of the largest individual windfalls from Anthropic's upcoming IPO. Bloomberg stresses that it is unclear whether Schmidt has sold part of his position since the initial investment. The available material offers no further details: neither the expected valuation, nor the size of the potential gain, nor the exact timing of the offering. We are not making them up.

The story is, in essence, one of timing. A bet of tens of millions at an early stage, held (if indeed it has been held) until the stock market debut, illustrates how much value has concentrated in those who got in when the risk was highest and the technology was still unproven.

Our take: headlines like this are easy to read as anecdotes about fortunes, but they are better seen as a symptom. In general, the capital that funds the AI frontier arrives early and is scarce, which is why returns concentrate in few hands. In the short term, the IPOs of labs like Anthropic will open that ownership to retail and institutional investors, which somewhat democratizes access to the value created, albeit late and at already very high prices.

There is also a governance angle. Schmidt is an influential figure in technology policy and in relations between industry and governments; that someone of his stature has direct financial interests in a leading lab implies no wrongdoing (the source does not suggest any), but it is a fact readers should keep in mind when weighing his public views on AI. Transparency about who profits from each narrative is basic hygiene for the debate.

The underlying thesis: the IPO is a financial validation, not proof that the transition will be fair. Whether AI's gains are shared broadly, and not just among early investors, will depend on how they translate into real abundance: medicine, productivity and accessible resources. That distribution is the true long-term test, and headlines about individual windfalls are only its first chapter.